News

Lexington Announces Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, Aug. 27, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that it has terminated its agreement with Gravitas Securities Inc. and Canaccord Genuity Corp. in connection with its previously announced brokered private placement (see news releases

Read More

Lexington Announces First Multicenter Clinical Study Site

Company embarks on pivotal clinical study VANCOUVER, British Columbia, Aug. 21, 2018 — Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the Medical College of Wisconsin as the first site in its multicenter clinical study for the HeartSentry portable cardiovascular health monitor. “Our

Read More

BLOG: The Endothelium: Getting to the “Heart” of Cardiovascular Disease

Despite positive developments in medication and lifestyle changes to reduce risk factors associated with cardiovascular disease (CVD) and atherosclerosis (plaque build-up in arteries), stroke and heart attack remain the leading cause of death worldwide. Innovation in medical care and medical devices will likely play a central role in improving long term cardiovascular health outcomes. Over

Read More

Lexington Biosciences Receives HeartSentry USPTO Patent Approval

Patent encompasses functional claims, underlying science and methods   VANCOUVER, British Columbia, July 25, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device. “Today’s news is a big deal for

Read More

Lexington Biosciences Announces Results of Annual General Meeting

VANCOUVER, British Columbia, July 02, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, wishes to provide the results of its recent Annual General Meeting. The Company is pleased to announce that all matters before the Board were approved at the Company’s Annual General Meeting (the “AGM”) held

Read More

Lexington Biosciences Concludes Initial HeartSentry Clinical Study

Company prepares for multicenter pivotal clinical study VANCOUVER, British Columbia, June 27, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo Clinical Research. “We are pleased with the performance of the

Read More

BLOG: Medtech Innovation Improving and Saving Lives

At Lexington Biosciences, we are passionate believers in medical technology (medtech) as a way of improving healthcare and quality of life for all.  Similarly, well known consumer brand giants are also gravitating towards the medtech space.  Just like us, they see a chance to help humanity and address a market that is nothing shy of

Read More

BLOG: Lexington Biosciences Applauds ACA and AHA Initiative to Lower Threshold for Hypertension and Recognition that More Diagnostics are Needed to Combat Heart Disease

Last November, the American College of Cardiology and American Heart Association jointly lowered their definition of hypertension from the previous 140/90 blood pressure reading down to 130/80.  Unfortunately, there isn’t necessarily a “one size fits all” standard due to an array of factors associated with high blood pressure, but there certainly is a well-known correlation

Read More

Lexington Biosciences Announces Amended Terms to Previously Announced Brokered Financing

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, June 11, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”) announces that it has amended the terms of its previously announced brokered private placement being led by Gravitas Securities Inc. and Canaccord Genuity Corp. (the “Agents”) (see news release

Read More

1 2 3 4

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News